Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure

Eur J Cancer. 2018 Jun:96:128-130. doi: 10.1016/j.ejca.2018.03.021. Epub 2018 Apr 18.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors*
  • B7-H1 Antigen / immunology
  • BRCA2 Protein / genetics*
  • Carcinoma / drug therapy*
  • Carcinoma / genetics
  • Carcinoma / immunology
  • Carcinoma / secondary
  • Cystectomy
  • Disease Progression
  • Drug Substitution
  • Humans
  • Male
  • Middle Aged
  • Molecular Diagnostic Techniques
  • Molecular Targeted Therapy
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Positron Emission Tomography Computed Tomography
  • Treatment Outcome
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / pathology
  • Urothelium / drug effects*
  • Urothelium / immunology
  • Urothelium / pathology
  • Urothelium / surgery

Substances

  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • BRCA2 Protein
  • BRCA2 protein, human
  • CD274 protein, human
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • olaparib